AMPE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AMPE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Ampio Pharmaceuticals's change in inventory for the quarter that ended in Dec. 2023 was $0.00 Mil. It means Ampio Pharmaceuticals's inventory stayed the same from Sep. 2023 to Dec. 2023 .
Ampio Pharmaceuticals's change in inventory for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means Ampio Pharmaceuticals's inventory stayed the same from Dec. 2022 to Dec. 2023 .
Ampio Pharmaceuticals's Total Inventories for the quarter that ended in Dec. 2023 was $0.00 Mil.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
The historical data trend for Ampio Pharmaceuticals's Change In Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ampio Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Change In Inventory | Get a 7-Day Free Trial | - | - | - | - | - |
Ampio Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Change In Inventory | Get a 7-Day Free Trial | - | - | - | - | - |
Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.
Change In Inventory for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ampio Pharmaceuticals (OTCPK:AMPE) Change In Inventory Explanation
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Ampio Pharmaceuticals's Days Inventory for the quarter that ended in is calculated as:
Days Inventory | = | Average Total Inventories | / | Cost of Goods Sold | * | Days in Period |
= | 0 | / | 0 | * | 365 / 4 | |
= | N/A |
2. Inventory Turnover measures how fast the company turns over its inventory within a year.
Ampio Pharmaceuticals's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as
Inventory Turnover | = | Cost of Goods Sold | / | Average Total Inventories |
= | 0 | / | 0 | |
= | N/A |
3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Ampio Pharmaceuticals's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as
Inventory-to-Revenue | = | Average Total Inventories | / | Revenue |
= | 0 | / | 0 | |
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Ampio Pharmaceuticals's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.
J Kevin Buchi | director | 41 MOORES ROAD, FRAZER PA 19355 |
Michael A Martino | director | C/O AMBIT BIOSCIENCES CORPORATION, 11080 ROSELLE STREET, SAN DIEGO CA 92121 |
David R Stevens | director | 300 ELLIOTT AVENUE WEST, SUITE 500, SEATTLE WA 98119-4114 |
Elizabeth Varki Jobes | director | 640 LEE ROAD, CHESTERBROOK PA 19087 |
Philip H Coelho | director | C/O THERMOGENESIS CORP, 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742 |
Holli Cherevka | officer: Chief Operating Officer | C/O AMPIO PHARMACEUTICALS, INC., 373 IVERNESS PARKWAY, ENGLEWOOD CO 80112 |
Dan Stokely | officer: CFO | 4810 EASTGATE MALL, SAN DIEGO CA 92121 |
Chilcott, Iii Thomas E. | officer: Chief Financial Officer | 373 INVERNESS PARKWAY, ENGLEWOOD CO 80122 |
Gregory A Gould | officer: Chief Financial Officer | 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660 |
Joshua R. Disbrow | officer: Chief Operating Officer | AMPIO PHARMACEUTICALS, INC., 5445 DTC PARKWAY, SUITE 925, GREENWOOD VILLAGE CO 80111 |
Michael Macaluso | director | C/O AMPIO PHARMACEUTICALS, INC., 5445 DTC PARKWAY, SUITE 925, GREENWOOD VILLAGE CO 80111 |
Richard B Giles | director | 5445 DTC PARKWAY, SUITE 925, GREENWOOD VILLAGE CO 80111 |
David Bar-or | director, officer: Chief Scientific Officer | C/O AMPIO PHARMACEUTICALS, INC., 373 INVERNESS PARKWAY, SUITE 200, ENGLEWOOD CO 80112 |
Vaughan Lennox Clift | officer: Chief Regulatory Affairs | 807 NOBLE SPRINGS ROAD, HOUSTON TX 77062 |
Mark D Mcgregor | officer: Chief Financial Officer | 5445 DTC PARKWAY, SUITE 925, GREENWOOD VILLAGE CO 80111 |
From GuruFocus
By PRNewswire PRNewswire • 07-05-2022
By Ds*** Ds*** • 09-01-2022
By PRNewswire PRNewswire • 08-19-2022
By PRNewswire PRNewswire • 04-18-2023
By PRNewswire PRNewswire • 10-13-2022
By PRNewswire PRNewswire • 11-08-2022
By PRNewswire PRNewswire • 01-17-2023
By PRNewswire • 10-31-2023
By PRNewswire PRNewswire • 08-24-2022
By PRNewswire • 09-26-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.